Cancer-focused Actuate is latest biotech on Nasdaq after $22.4M IPO

Actuate Therapeutics became the latest biotech to join the Nasdaq this week with a scaled-back IPO that brought in $22.4 million.

The Texas- and Ireland-based company had initially outlined plans in July for a $45.1 million offering but soon reduced this to closer to the $22 million mark.